Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643530 | 0.79 | RAB9A (0.54) | RAB9AGAALTA4HCDK2FLT4 | |
| SCHEMBL22851453 | 0.78 | RAB9A (0.53) | CHRNA7RAB9ACYP2C19CHRNB2CHRNA4 | |
| SCHEMBL9640902 | 0.78 | KCNA5 (0.45) | RAB9ACHRNB2CHRNA4SMN1; SMN2 | |
| SCHEMBL6032869 | 0.77 | CYP2C19 (0.50) | CYP2C19GAAHRH3 | |
| SCHEMBL171395 | 0.77 | ALDH1A1 (0.56) | CYP2C19GAA | |
| SCHEMBL4507702 | 0.76 | LMNA (0.53) | RAB9ACYP2C19SMN1; SMN2CDK2FLT4 | |
| SCHEMBL7999576 | 0.76 | HDAC3 (0.53) | RAB9AGAALTA4HCDK2FLT4 | |
| SCHEMBL4572901 | 0.76 | RAB9A (0.50) | CHRNA7RAB9AGAALTA4HCDK2 | |
| SCHEMBL4383419 | 0.76 | RAB9A (0.50) | RAB9AGAALTA4HCDK2FLT4 | |
| SCHEMBL15055378 | 0.76 | RAB9A (0.50) | RAB9AGAALTA4HCDK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-20240092791-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-4203988-A | ANTISECRETORY AGENTS | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092791-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CHRNA7 1784/4885RAB9A 391/4885CYP2C19 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.